亚什兰(ASH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ASH 亚什兰

盘前交易 12-23 07:48:41 EST

71.88

-0.07

-0.10%

盘前73.00

+1.15+1.60%

07:28 EST

最高73.43	最低71.56	成交量116.53万
今开71.70	昨收71.95	日振幅2.59%
总市值33.86亿	流通市值31.57亿	总股本4,711万
成交额8,434万	换手率2.65%	流通股本4,393万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ASH","market":"US","secType":"STK","nameCN":"亚什兰","latestPrice":71.881,"timestamp":1734728398268,"preClose":71.95,"halted":0,"volume":1165273,"hourTrading":{"tag":"盘前","latestPrice":73,"preClose":71.85,"latestTime":"07:28 EST","volume":8,"amount":579.12,"timestamp":1734956902426},"delay":0,"floatShares":43925673,"shares":47109326,"eps":3.35,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.069,"latestTime":"12-23 07:48:41 EST","open":71.7,"high":73.425,"low":71.56,"amount":84342580.928392,"amplitude":0.025921,"askPrice":73.5,"askSize":100,"bidPrice":65,"bidSize":1,"shortable":3,"etf":0,"ttmEps":3.35,"exchange":"NYSE","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734964200000},"adr":0,"adjPreClose":71.85,"adrRate":0,"dividendRate":0.021981,"preHourTrading":{"tag":"盘前","latestPrice":73,"preClose":71.85,"latestTime":"07:28 EST","volume":8,"amount":579.12,"timestamp":1734956902426},"postHourTrading":{"tag":"盘后","latestPrice":71.85,"preClose":71.85,"latestTime":"16:15 EST","volume":197801,"amount":14212001.516,"timestamp":1734729357594},"volumeRatio":2.0328731923284558,"impliedVol":0.2787,"impliedVolPercentile":0.6},"requestUrl":"/m/hq/s/ASH","defaultTab":"news","newsList":[{"id":"2491680204","title":"基石药业-B现涨逾4% 将于ASH年会公布CS5001针对晚期淋巴瘤最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2491680204","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491680204?lang=zh_cn&edition=full","pubTime":"2024-12-16 11:29","pubTimestamp":1734319740,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　基石药业-B（02616）早盘上涨3.80%，现报2.73港元，成交额1450.93万港元。\n　　近日，基石药业-B公布，将在第66届美国血液学会（ASH）年会上，公布管线2.0重磅产品CS5001（ROR1 ADC）针对淋巴瘤的最新临床数据。公告指出，CS5001是目前已知首个在实体瘤和淋巴瘤中均观察到临床疗效的ROR1 ADC。本次ASH年会的公布突出CS5001作为单药治疗晚期淋巴瘤的最新安全性和疗效数据。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-16/doc-inczrkux2813318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4109","BK1574","LU2463526074.USD","BK1161","ASH","02616"],"gpt_icon":0},{"id":"2491680666","title":"港股异动 | 基石药业-B(02616)涨超3% 将于ASH年会公布CS5001针对晚期淋巴瘤最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2491680666","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491680666?lang=zh_cn&edition=full","pubTime":"2024-12-16 11:23","pubTimestamp":1734319420,"startTime":"0","endTime":"0","summary":"消息面上，近日，基石药业-B公布，将在第66届美国血液学会年会上，公布管线2.0重磅产品CS5001针对淋巴瘤的最新临床数据。公告指出，CS5001是目前已知首个在实体瘤和淋巴瘤中均观察到临床疗效的ROR1 ADC。本次ASH年会的公布突出CS5001作为单药治疗晚期淋巴瘤的最新安全性和疗效数据。另外，CS5001全球多中心临床试验目前仍在美国、澳洲和中国同步进行，目前剂量递增已完成，近期公司将启动涵盖多瘤种、具有注册潜力的Ib期剂量扩展研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","02616","BK4109","BK1161","ASH","BK1574"],"gpt_icon":0},{"id":"2490879568","title":"港股异动 | 科济药业-B(02171)涨幅扩大至40% 公司在ASH年会上展示多项成果 通用型CAR-T早期数据优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2490879568","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490879568?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:02","pubTimestamp":1733904155,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B尾盘涨幅扩大至40%，截至发稿，涨39.35%，报10.66港元，成交额6.47亿港元。国投证券指出，根据公司2024年ASH年会披露的同种异体CAR-T药物CT0590的早期临床数据，CT0590已显示出可控的安全性，并在多名患者中实现了深度和持久的临床缓解，其未来更多样本量的数据值得静待。此外，目前已有多个研究表明出CAR-T药物在自身免疫疾病显示出临床治愈的潜力，未来公司CAR-T产品在自身免疫疾病领域的应用值得静待。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02171","BK1585","BK1587","BK1574","BK4022","LU2463526074.USD","BK4109","ASH","CAR","BK1161","BK4230"],"gpt_icon":0},{"id":"2490600917","title":"港股异动 | 科济药业-B(02171)急升逾16% 公司在ASH年会展示赛恺泽、CT071和CT0590研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2490600917","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490600917?lang=zh_cn&edition=full","pubTime":"2024-12-11 11:43","pubTimestamp":1733888619,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B急升逾16%，截至发稿，涨15.69%，报8.85港元，成交额1.26亿港元。消息面上，科济药业公布，CT0590、CT071和赛恺泽的更新结果已在第66届美国血液学会年会上进行报告。此外，公司此前公布，美国FDA已解除在美国的泽沃基奥仑赛注射液、舒瑞基奥仑赛注射液以及CT071的临床试验暂停。所述临床试验暂停与2023年12月FDA对公司位于北卡罗来纳州达勒姆的临床生产基地进行检查后发布的发现项有关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02171","BK1585","BK1587","BK1574","LU2463526074.USD","BK4109","ASH","BK1161"],"gpt_icon":0},{"id":"2490098892","title":"ASH数据出炉：隐藏的ADC王者","url":"https://stock-news.laohu8.com/highlight/detail?id=2490098892","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490098892?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:58","pubTimestamp":1733824688,"startTime":"0","endTime":"0","summary":"在血液瘤领域，ADC的预期变得越来越明确。2023年销售额超过10亿美元的ADC中，辉瑞的Adcetris位居第二，罗氏的Polivy销售额也直逼10亿美元。复发是血液瘤难以逃脱的问题，而ADC与化疗、免疫治疗的机制并不相同，因此在血液瘤的后线治疗中仍能占据一席之地。另一方面，ADC还能成为前线疗法的有效手段。而在2024 ASH年会上，基石药业发布的CS5001最新临床数据，进一步引起了市场对于ROR1 ADC的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/246622","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU2463526074.USD","BK4080","ASH","BK4109","ADC","BK4231"],"gpt_icon":0},{"id":"2490940064","title":"金斯瑞生物科技(01548)：传奇生物宣布于2024年ASH年会上公布报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2490940064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490940064?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:14","pubTimestamp":1733822078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技 发布公告，于2024年12月10日，传奇生物科技股份有限公司已发布新闻稿，公布了3期研究CARTITUDE-4最新数据。MRD阴性率是多发性骨髓瘤患者生存期延长的重要预后标志。MRD阴性率的研究结果已在加利福尼亚州圣地牙哥举行的第66届美国血液学会年会暨展览会上以口头报告的形式发表。研究进行了随机分组，208名患者接受CARVYKTI治疗，211名患者接受标准疗法。截至目前，CARVYKTI已在全球五个国家推出，治疗患者人数逾4500名。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","HK0000320223.HKD","01548","BK4139","BK4585","ASH","BK4588","HK0000306701.USD","BK1576","BK4505","BK4109","HK0000320264.USD","LEGN","BK1141","HK0000306685.HKD","BK1583"],"gpt_icon":0},{"id":"2490696260","title":"科济药业-B(02171)于2024年ASH年会上呈列的赛恺泽®、CT071 和CT0590的研究成果更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2490696260","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490696260?lang=zh_cn&edition=full","pubTime":"2024-12-10 16:32","pubTimestamp":1733819537,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B 公布，CT0590、CT071和赛恺泽 的更新结果已在第66届美国血液学会年会上进行报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02171","ASH","BK1587","BK1585","BK4109","BK1574","LU2463526074.USD"],"gpt_icon":0},{"id":"2490864365","title":"2024 ASH | 与标准治疗相比，CARVYKTI® 显著提高了复发或难治性多发性骨髓瘤患者MRD阴性率","url":"https://stock-news.laohu8.com/highlight/detail?id=2490864365","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490864365?lang=zh_cn&edition=full","pubTime":"2024-12-10 13:16","pubTimestamp":1733807760,"startTime":"0","endTime":"0","summary":"\" 3期研究CARTITUDE-4评估了CARVYKTI与PVd 或 DPd 的标准疗法在既往接受过一至三线治疗且来那度胺耐药的复发或难治性多发性骨髓瘤成人患者中的疗效。研究进行了随机分组，208名患者接受CARVYKTI治疗，211名患者接受标准治疗。此外，经CARVYKTI 治疗的患者迅速达到了较高的总体MRD阴性率，在第56天时，69%的可评估患者已达到MRD阴性。截至目前，我们已在全球五个国家推出了CARVYKTI，治疗患者人数逾4500名。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4576011_ZH76011_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2463526074.USD","BK4585","BK4139","ASH","BK4588","BK4505","LEGN","BK4109"],"gpt_icon":0},{"id":"2490035364","title":"12月10日操盘必读：影响股市利好或利空消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2490035364","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490035364?lang=zh_cn&edition=full","pubTime":"2024-12-10 08:35","pubTimestamp":1733790900,"startTime":"0","endTime":"0","summary":"　　1、中共中央政治局12月9日召开会议，分析研究2025年经济工作；听取中央纪委国家监委工作汇报，研究部署2025年党风廉政建设和反腐败工作。　　2、昨日，李强同主要国际经济组织负责人举行“1+10”对话会。　　3、韩国法务部当地时间12月9日表示，对总统尹锡悦实施禁止出境措施。“叙利亚救国政府”由叙反对派成立，巴希尔担任其总理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/cpbd/2024-12-10/doc-incyxrwt2028158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4218","PK","BK4181","BK4109","ASH","LU2463526074.USD"],"gpt_icon":0},{"id":"2490403353","title":"股海导航 12月10日沪深股市公告与交易提示","url":"https://stock-news.laohu8.com/highlight/detail?id=2490403353","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490403353?lang=zh_cn&edition=full","pubTime":"2024-12-10 08:34","pubTimestamp":1733790840,"startTime":"0","endTime":"0","summary":"　　三连板梅雁吉祥12月9日晚间发布风险提示，公司全资子公司梅州市梅雁矿业有限公司拥有的嵩溪锑银矿位于梅州市梅县区白渡镇，开采矿种类型为银矿、锑矿，采矿许可证有效期限自2022年5月至2032年5月。公司于2023年6月聘请北京地心互动科技有限公司对嵩溪锑银矿区深部矿区进行详查及找矿工作。截至目前，勘查和深部探矿工作暂未完成，嵩溪锑银矿目前未进行开采。公司将严格遵照相关规定对相关事项及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-12-10/doc-incyxrwt2027560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PK","LU2463526074.USD","ASH","BK4218","BK4181","BK4109"],"gpt_icon":0},{"id":"2490748167","title":"康诺亚-B(02162)：CM336 I/II期临床研究最新数据在第66届美国血液学会(ASH)年会上以壁报形式公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2490748167","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490748167?lang=zh_cn&edition=full","pubTime":"2024-12-09 16:32","pubTimestamp":1733733168,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B 发布公告，其靶向BCMAxCD3的双特异性抗体CM336治疗复发或难治性多发性骨髓瘤的I/II期临床研究最新数据在第66届美国血液学会年会上以壁报形式公布。截至2024年10月30日，该研究共入组68例受试者。安全性评估显示，CM336安全性和耐受性良好。剂量成功递增至160 mg，且尚未达到最大耐受剂量。CM336在治疗复发或难治性多发性骨髓瘤受试者中表现出初步有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4109","BK1574","BK1587","02162","BK1161","BK1583","LU2463526074.USD","ASH"],"gpt_icon":0},{"id":"2490648977","title":"令人鼓舞的疗效和安全性 基石药业在ASH年会上公布CS5001针对晚期淋巴瘤的最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2490648977","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490648977?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:54","pubTimestamp":1733705682,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月9日，基石药业宣布，公司在第66届美国血液学会年会上公布管线2.0重磅产品CS5001针对淋巴瘤的最新临床数据。CS5001是目前已知首个在实体瘤和淋巴瘤中均观察到临床疗效的ROR1 ADC。CS5001全球多中心试验目前仍在美国、澳大利亚和中国同步进行，目前剂量递增已完成，近期我们将启动涵盖多瘤种、具有注册潜力的1b期剂量扩展研究。安全性数据剂量递增已完成，截至目前在10个剂量水平上均未报告DLT。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02616","BK4109","LU2463526074.USD","ASH","BK1161"],"gpt_icon":0},{"id":"2490769284","title":"和誉-B：和誉医药在ASH年会上展示匹米替尼治疗cGvHD的初步II期积极研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2490769284","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490769284?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:16","pubTimestamp":1733703360,"startTime":"0","endTime":"0","summary":"　　和誉-B发布公告，公司的附属公司上海和誉生物医药科技有限公司在第66届美国血液学会年会上以口头报告形式发布了匹米替尼治疗既往一线或多线治疗失败的慢性移植物抗宿主病患者的初步II期研究结果。尽管大多数入组患者尚未完成cGvHD缓解评估所需的6个月治疗周期，但是其中接受匹米替尼20毫克QD 治疗患者亚组的初步数据显示ORR已达64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-09/doc-incyvhrw9800882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","ASH","02256","BK1574","LU2463526074.USD","BK1515","09939","BK1161","LU2488822045.USD","BK4109"],"gpt_icon":0},{"id":"2489738229","title":"和誉-B(02256)：和誉医药在第66届ASH年会上展示匹米替尼治疗cGvHD的初步II期积极研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2489738229","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489738229?lang=zh_cn&edition=full","pubTime":"2024-12-08 19:19","pubTimestamp":1733656757,"startTime":"0","endTime":"0","summary":"尽管大多数入组患者尚未完成cGvHD缓解评估所需的6个月治疗周期，但是其中接受匹米替尼20毫克QD 治疗患者亚组的初步数据显示ORR已达64%。这些数据共同证明了匹米替尼治疗cGvHD相关的BOS的临床疗效。研究结果表明，匹米替尼在接受多种既往治疗的cGvHD患者中，表现出显著的临床疗效和良好的耐受性。基于最新的临床经验，匹米替尼可能为治疗cGvHD提供一种有前景的全新治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","LU2488822045.USD","09939","LU2463526074.USD","BK4109","02256","ASH","159938","BK1161"],"gpt_icon":0},{"id":"2489885464","title":"港股异动 | 科济药业-B(02171)涨超5% 赛恺泽®、CT071和CT0590数据即将于2024年ASH年会上展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2489885464","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489885464?lang=zh_cn&edition=full","pubTime":"2024-12-05 14:45","pubTimestamp":1733381117,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B涨超5%，截至发稿，涨5.75%，报6.8港元，成交额3279.07万港元。消息面上，科济药业此前宣布其产品赛恺泽、CT071和CT0590的数据将在第66届美国血液学会年会上以壁报形式展示，会议将于12月7日至10日举行。科济药业靶向BCMA的通用型CAR-T产品CT0590的首个人体一期试验中，共入组5名受试者，中位随访时间16.6个月。其中3例患者获得缓解，包括2例严格完全缓解和1例部分缓解。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","BK4109","BK1585","BK1161","BK1587","02171","BK1574","ASH"],"gpt_icon":0},{"id":"2486063108","title":"美国研究综述-多米诺比萨、弹性 NV、雪花","url":"https://stock-news.laohu8.com/highlight/detail?id=2486063108","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486063108?lang=zh_cn&edition=full","pubTime":"2024-11-26 05:38","pubTimestamp":1732570699,"startTime":"0","endTime":"0","summary":"美国研究综述-多米诺比萨、弹性 NV、雪花路透社11月25日 - 华尔街证券分析师周一调整了对多米诺比萨、Elastic NV 和 Snowflake 等几家美国上市公司的评级和目标价。要点 * 多米诺比萨公司DPZ.N：TD Cowen将目标价从475美元上调至515美元 * Elastic NV ESTC.N：Wedbush将其评级从 \"中性 \"上调至 \"跑赢大盘\"。* Thor Industries Inc THO.N：CFRA将目标价从90美元上调至115美元 以下是路透社周一报导的美国公司研究报告摘要。* Edwards Lifesciences Corp EW.N：Leerink Partners将目标价从73美元上调至74美元 * Ehealth Inc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nL3T3MW0XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVS","DPZ","AKR","COLB","EW","KR","ACHC","LU0345770993.USD","CSWI","DXLG","LU0072461881.USD","LU1429558221.USD","EWCZ","CARM","BKR","EQT","ADVM","BK","DXCM","BERY","LU2125909759.SGD","DTM","AZEK","LU1861559042.SGD","BK4505","CYH","AMGN","BJ","EDIT","BBIO","LU1548497426.USD","BK4581","DASH","CCAP","EHC","BURL","DE","BK4106","CFLT","ASH","ESTC","CHWY","LU2211817866.USD","BMRN","CRL"],"gpt_icon":1},{"id":"2485258260","title":"细胞凋亡疗法的“关键一跃”","url":"https://stock-news.laohu8.com/highlight/detail?id=2485258260","media":"锦缎","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485258260?lang=zh_cn&edition=full","pubTime":"2024-11-22 18:46","pubTimestamp":1732272412,"startTime":"0","endTime":"0","summary":"极有可能成为中国首款，全球第二款细胞凋亡疗法。细胞凋亡疗法即将迎来“关键一跃”，一个崭新的时代或许就要开启。维奈克拉是目前唯一一款上市的细胞凋亡疗法药物，一经上市即获得了投资者的热切关注，并且不负众望的成为营收超20亿美元的重磅药物。无可否认，维奈克拉是一款成功的药物，它成功开启了细胞凋零疗法的大门，并且已经取得了商业化的成功。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8eirccCcNZ7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["LU2463526074.USD","BK4097","ASH","BK4109","TLS"],"gpt_icon":0},{"id":"2483169306","title":"Ashland Inc.2024财年实现净利润1.99亿美元，同比增加18.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483169306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483169306?lang=zh_cn&edition=full","pubTime":"2024-11-16 00:00","pubTimestamp":1731686432,"startTime":"0","endTime":"0","summary":"11月16日，Ashland Inc.公布财报，公告显示公司2024财年净利润为1.99亿美元，同比增加18.45%；其中营业收入为21.13亿美元，同比减少3.56%，每股基本收益为--。机构评级：截至2024年11月16日，当前有9家机构对Ashland Inc.目标价做出预测，其中目标均价为98.33美元，其中最低目标价为92.00美元，最高目标价为105.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000251abc515b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000251abc515b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASH"],"gpt_icon":0},{"id":"2482170212","title":"港股异动 | 和誉-B(02256)逆市涨超7% 将于ASH会议展示慢性移植物抗宿主病新药初步研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2482170212","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482170212?lang=zh_cn&edition=full","pubTime":"2024-11-11 09:38","pubTimestamp":1731289081,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B逆市涨超7%，截至发稿，涨7.11%，报2.58港元，成交额1161.03万港元。消息面上，和誉-B发布公告，该公司的附属公司上海和誉生物医药科技有限公司宣布，和誉医药将在第66届美国血液学会年会上以口头报告形式发布其自主研发的CSF-1R抑制剂匹米替尼的一项II期研究数据。此研究调查匹米替尼于治疗既往一线或多线治疗失败的慢性移植物抗宿主病 患者的应用情况。此次ACoP大会将于2024年11月10日至13日在美国菲尼克斯举行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","ASH","BK1161","02256","LU2488822045.USD","BK4109"],"gpt_icon":0},{"id":"2481110389","title":"港股异动 | 和誉-B(02256)午后涨超13% 和誉医药将在ASH年会发布匹米替尼的初步II期研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2481110389","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481110389?lang=zh_cn&edition=full","pubTime":"2024-11-08 15:03","pubTimestamp":1731049380,"startTime":"0","endTime":"0","summary":"消息面上，和誉公布，附属和誉医药将在2024年12月7日至10日于美国加利福尼亚州圣地亚哥举行的第66届美国血液学会年会上，展示其自主研发的CSF-1R抑制剂匹米替尼在治疗慢性移植物抗宿主病患者的初步II期研究结果。此次研究专注于治疗既往一线或多线治疗失败的cGvHD患者。公告中提到，cGvHD是异基因造血干细胞移植后常见的并发症，约30%至70%的患者会发生此病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","LU2488822045.USD","BK1574","BK1161","LU2463526074.USD","ASH","09939","159938","BK4109","02256"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ashland.com","stockEarnings":[{"period":"1week","weight":-0.0388},{"period":"1month","weight":-0.0568},{"period":"3month","weight":-0.1768},{"period":"6month","weight":-0.2579},{"period":"1year","weight":-0.1568},{"period":"ytd","weight":-0.1474}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ashland Inc.是特拉华州的一家公司。亚什兰是为广泛的消费和工业市场客户提供特种材料的全球领导者，包括粘合剂、建筑涂料、建筑、能源、食品和饮料、营养保健品、个人护理和制药。亚什兰为100多个国家的客户提供服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.005621},{"month":2,"riseRate":0.477273,"avgChangeRate":0.002295},{"month":3,"riseRate":0.636364,"avgChangeRate":0.040159},{"month":4,"riseRate":0.577778,"avgChangeRate":0.048415},{"month":5,"riseRate":0.622222,"avgChangeRate":0.022034},{"month":6,"riseRate":0.466667,"avgChangeRate":-0.00655},{"month":7,"riseRate":0.377778,"avgChangeRate":-0.007381},{"month":8,"riseRate":0.533333,"avgChangeRate":0.000964},{"month":9,"riseRate":0.4,"avgChangeRate":-0.014544},{"month":10,"riseRate":0.466667,"avgChangeRate":-0.006498},{"month":11,"riseRate":0.6,"avgChangeRate":0.008634},{"month":12,"riseRate":0.533333,"avgChangeRate":0.013616}],"exchange":"NYSE","name":"亚什兰","nameEN":"Ashland"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚什兰(ASH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚什兰(ASH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚什兰,ASH,亚什兰股票,亚什兰股票老虎,亚什兰股票老虎国际,亚什兰行情,亚什兰股票行情,亚什兰股价,亚什兰股市,亚什兰股票价格,亚什兰股票交易,亚什兰股票购买,亚什兰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚什兰(ASH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚什兰(ASH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}